Introduction to Journal of Thoracic Disease new column: Critical Care Frontier and Horizon
Bibliographic record
Abstract
It is my great pleasure to introduce our new column of Critical Care Frontier and Horizon in the Journal of Thoracic Disease.This column designs to feature original investigations, review articles, expert opinions, editorial and case report series in critical care medicine.Our mission in the Critical Care Frontier and Horizon is to collect the latest development of critical care medicine that will be freely available to clinicians, researchers, stakeholders and publics who are interested.The term "adult respiratory distress" was used by Ashbaugh et al. in 1967 (1) to describe 12 adult patients who had acute onset of tachypnea, hypoxemia, and loss of lung compliance after a variety of physical and biochemical insults such as hypoxemia, trauma, aspiration, and viral infection.The modern term "acute respiratory distress syndrome (ARDS)" is categorized from mild, moderate to severe form of the lung disorder as per the recent Berlin definition (2).The hospital mortality of ARDS remains at approximately 35% (3).Numerous investigative studies aiming at the treatment of underlying diseases or its physiological consequences have failed to reduce ARDS mortality, and management remains supportive with lung-protective mechanical ventilation (4).A promising approach is investigating cell-based therapy for ARDS.This is cutting-edge research, using mesenchymal stromal cells (MSCs) as drugs to help to repair lung damage.In this inaugural column of Critical Care Frontier and Horizon at the Journal of Thoracic Disease, Dr. Horie and colleagues provide an excellent comprehensive overview in the fields of cell therapy in ARDS.The authors summarize updated results of preclinical experiments and clinical studies, outline mechanisms of action of MSCs, and discuss potential challenge of cell therapy and future research direction.We are hoping that this review article will help physicians, scientists and shareholders understand the current status of MSC therapy in ARDS and encourage translational research collaboration between basic and clinical investigators to help shape the future cell therapy.Finally, we are delighted to call for papers in this column-Critical Care Frontier and Horizon-that serves as an open platform for rapid publication of advanced basic and clinical research.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.023 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.004 | 0.002 |
| Science and technology studies | 0.003 | 0.003 |
| Scholarly communication | 0.012 | 0.005 |
| Open science | 0.002 | 0.002 |
| Research integrity | 0.006 | 0.016 |
| Insufficient payload (model declined to judge) | 0.066 | 0.035 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".